Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

What’s New in Polymyalgia Rheumatica?

Jason Liebowitz, MD, FACR  |  July 31, 2024

Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.

Filed under:ConditionsEULAR/OtherGuidanceMeeting ReportsPain Syndromes Tagged with:EULAR 2024GCAgiant cell arteritis (GCA)PMRPolymyalgia Rheumatica

Editor's Pick

The ACR and CHEST Release 2 New ILD Guidelines

Ruth Jessen Hickman, MD  |  July 9, 2024

Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceOther Rheumatic ConditionsRheumatoid ArthritisSjögren’s DiseaseSystemic Sclerosis Tagged with:Editor's PickILDInterstitial Lung Diseaseinterstitial lung disease (ILD)

CAR-T Cell Therapy in Autoimmune Disease: The Next Frontier

Jason Liebowitz, MD, FACR  |  July 2, 2024

Chimeric antigen receptor (CAR) T cell therapy has the potential to fundamentally shift the treatment of autoimmune disease. During his presentation at EULAR 2024, Georg Schett, MD, provided an overview of this treatment process and described the promising findings of the latest research.

Filed under:Biologics/DMARDsConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:CAR-T cell therapychimeric antigen receptor T (CAR-T) cellsEULAR 2024ImmunologyResearchSLE Resource Centersystemic lupus erythematosus (SLE)

Telehealth Triage Study Seeks to Close Gaps in Care

Gretchen Henkel  |  May 5, 2024

Reducing the time to diagnosis and initiation of appropriate treatment is paramount to intercept inflammatory damage in patients at the onset of rheumatic disease. But those targets can be delayed by provider shortages and other barriers to care. Since last June, Remission Medical, a virtual rheumatology clinic, has been partnering with Mayo Clinic to find…

Filed under:Practice SupportTechnology Tagged with:DiagnosisMayo Clinictelehealthtriage

Case Report: Persistent Pruritic Plaques in Adult-Onset Still’s Disease

Kubra Bugdayli, MD, Ahmed Eldaboush, MD, Sanjana Aggarwal, MBBS, & Bonnie Bermas, MD  |  May 5, 2024

Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder characterized by persistent fever at regular intervals, arthralgias or arthritis, rash, sore throat and neutrophilic leukocytosis.1,2 Significant elevation in ferritin levels is characteristic and tends to correlate with disease activity. Additional clinical features may include myalgias, lymphadenopathy, hepatosplenomegaly, serositis, myocarditis, abnormal liver function tests and development…

Filed under:ConditionsMyositisOther Rheumatic Conditions Tagged with:adult onset Still's diseasecase reportdermatomyositisdermatomyositis (DM)Fellows Forummalignancymimics

Polymyalgia Rheumatica: New Tricks for an Old Disease

Desh Nepal, MD, Sebastian E. Sattui, MD, MS, & Michael Putman, MD, MS  |  January 29, 2024

Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

Filed under:ACR ConvergenceConditionsMeeting ReportsSoft Tissue Pain Tagged with:ACR Convergence 2022Disease-modifying antirheumatic drugs (DMARDs)GlucocorticoidsIL-6IL-6 inhibitorsimagingPMR FocusRheumPolymyalgia Rheumatica

Study Assesses Sarilumab for Polymyalgia Rheumatica

Ruth Jessen Hickman, MD  |  January 25, 2024

In an ACR Convergence 2022 session, Robert Spiera, MD, director of the Scleroderma, Vasculitis, and Myositis Center at the Hospital for Special Surgery, New York City, discussed the use of sarilumab as a potential glucocorticoid-sparing therapy in a phase 3 study in patients with treatment-refractory polymyalgia rheumatica (PMR), one of the most common inflammatory diseases…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:IL-6IL-6 inhibitorsPMR FocusRheumPolymyalgia RheumaticaResearch Reviewsarilumabsteroid-sparing therapies

How to Treat Refractory Polymyalgia Rheumatica

Katie Robinson  |  January 25, 2024

Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:glucocorticoid resistantIL-6IL-6 inhibitorsPMR FocusRheumPolymyalgia RheumaticaResearch Reviewsarilumab

Study: Most Patients with PMR Aren’t Getting Steroid-Sparing Agents in First 2 Years

Katie Robinson  |  January 25, 2024

A minority of patients with polymyalgia rheumatica (PMR) who were new to rheumatology practice were prescribed steroid-sparing agents through two years of follow-up. This is according to a large, U.S.-based cohort study, published in Arthritis Care & Research, which also found that nearly two-thirds of the patients remained on glucocorticoids beyond one year.1 “Our study…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:GlucocorticoidsMethotrexatePMR FocusRheumPolymyalgia RheumaticaResearch Reviewsteroid-sparing therapies

How Prevalent Is Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica?

Colm Kirby, MB, BCh, BAO, MRCPI, Rachael Flood, MB, BCh, BAO, MRCPI, Ronan Mullan, MB, BCh, BAO, MRCPI, Grainne Murphy, MB, BCh, BAO, MRCPI, & David Kane, MB, BCh, BAO, MRCPI  |  January 24, 2024

Background/Purpose It has been reported that 20–50% of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). The natural history of ultrasound-defined subclinical GCA in PMR is not known. Methods Twenty-five newly diagnosed PMR patients who met a clinical diagnosis for PMR, verified by two rheumatologists, were examined by ultrasound. All six branches…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch RheumVasculitis Tagged with:Giant Cell Arteritisgiant cell arteritis (GCA)glucocorticoid resistantimagingPMR FocusRheumPolymyalgia RheumaticaResearch Review

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 29
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences